Pulmonary Cell News Volume 9.42 | Oct 29 2020

May 12, 2022

2020-29-10 | PULCN 9.42

Pulmonary Cell News by STEMCELL Technologies

Vol. 9.42 – 29 October, 2020

TOP STORY

Identification of SARS-CoV-2 Inhibitors using Lung and Colonic Organoids

As SARS-CoV-2 primarily infects the respiratory tract, investigators developed a lung organoid model using human pluripotent stem cells (hPSCs), and generated complementary hPSC-derived colonic organoids to explore the response of colonic cells to SARS-CoV-2 infection.
[Nature]

Full Article

Grow Functional Airway Organoids with PneumaCult™

PUBLICATIONSRanked by the impact factor of the journal

Exuberant Fibroblast Activity Compromises Lung Function via ADAMTS4

The authors demonstrated that respiratory viral infection induces distinct fibroblast activation states, which they term extracellular matrix-synthesizing, damage-responsive and interferon-responsive states. They provide evidence that excess activity of damage-responsive lung fibroblasts drives lethal immunopathology during severe influenza virus infection.
[Nature]

Full Article

Mutant CFTR Drives TWIST1 Mediated Epithelial–Mesenchymal Transition

Researchers investigated the occurrence of epithelial–mesenchymal transition (EMT) in airways native tissue, primary cells and cell lines expressing mutant cystic fibrosis transmembrane conductance regulator through the expression of epithelial and mesenchymal markers as well as EMT-associated transcription factors.
[Cell Death & Disease]

Full Article

The
SARS-CoV-2 Targets by the PscRNA Profiling of ACE2, TMPRSS2 and Furin Proteases

Scientists incorporated protein information to analyze the expression of ACE2, the SARS-CoV-2 receptor, together with co-factors, TMPRSS2 and Furin, at single cell level in situ, which they called protein-proofed single-cell RNA (pscRNA) profiling.
[iScience]

Abstract Full Article
Graphical Abstract

A
High Content Screen for Mucin-1-Reducing Compounds Identifies Fostamatinib as a Candidate for Rapid Repurposing for Acute Lung Injury

In vivo, Fostamatinib reduced Mucin-1 (MUC1) abundance in lung epithelial cells in a mouse model of acute lung injury. In vitro, SYK inhibition by the active metabolite R406 promoted MUC1 removal from the cell surface.
[Cell Reports Medicine]

Abstract Full Article
Graphical Abstract

LUNG CANCER

Upregulation
of KCNQ1OT1 Promotes Resistance to Stereotactic Body Radiotherapy in Lung Adenocarcinoma by Inducing ATG5/ATG12-Mediated Autophagy via miR-372-3p

Differential lncRNAs were screened by microarray assay, then the expression was detected in LUAD tumor tissues and cell lines by qPCR. The influence on radiation response was assessed via in vitro and in vivo assays, and autophagy levels were evaluated by western blot and transmission electron microscopy.
[Cell Death & Disease]

Full Article

SASH1
Is a Prognostic Indicator and Potential Therapeutic Target in Non-Small Cell Lung Cancer

Scientists showed that low SAM and SH3 domain-containing protein 1 (SASH1) mRNA expression was associated with poor survival in adenocarcinoma. Supporting this, modulation of SASH1 levels in a panel of lung cancer cell lines mediated changes in cellular proliferation and sensitivity to cisplatin.
[Scientific Reports]

Full Article

Plasma-Activated
Medium as Adjuvant Therapy for Lung Cancer with Malignant Pleural Effusion

Researchers compared effects of plasma-activated medium with effects of conventional clinical thermal therapy on both lung cancer cells and benign cells for management of malignant pleural effusion.
[Scientific Reports]

Full Article

ERK3/MAPK6 Is Required for KRAS-Mediated NSCLC Tumorigenesis

Investigators uncovered that ERK3, a ubiquitously expressed atypical MAPK, was required for KRAS-mediated NSCLC tumors. ERK3 is highly expressed in lung cancers, and oncogenic KRAS led to the activation and stabilization of the ERK3 protein.
[Cancer Gene Therapy]

Full Article

Lung
Gene Expression Signatures Suggest Pathogenic Links and Molecular Markers for Pulmonary Tuberculosis, Adenocarcinoma and Sarcoidosis

The authors revealed a distinct ossification-related tuberculosis (TB) lung signature, which may be associated with the activation of the BMP/SMAD/RUNX2 pathway in Mycobacterium tuberculosis-infected macrophages that can restrain mycobacterial survival and promote osteogenic differentiation of mesenchymal stem cells.
[Communications Biology]

Full Article

Request your free copy of the 'Directed Differentiation of Pluripotent Stem Cells' Wallchart

REVIEWS

Less
Is More: Rare Pulmonary Neuroendocrine Cells Function as Critical Sensors in Lung

Investigators explore topics of pulmonary neuroendocrine cell (PNEC) development; PNEC interaction with other lung structural cells, immune cells, and lung-innervating neurons; PNEC activation; and emerging knowledge on their physiological and pathological roles.
[Developmental Cell]

Full Article

INDUSTRY AND POLICY NEWS

Arcus to Collaborate with AstraZeneca on Registrational Trial for Domvanalimab, Arcus’s Novel Anti-TIGIT Antibody, Plus Imfinzi^® in Stage III NSCLC

Arcus Biosciences, Inc. announced a collaboration with AstraZeneca to evaluate domvanalimab, Arcus’s investigational anti-TIGIT antibody, in combination with Imfinzi in a registrational Phase III clinical trial in patients with unresectable Stage III non-small cell lung cancer (NSCLC).
[Arcus Biosciences, Inc.]

Press Release

aTyr
Pharma Announces Research Collaboration with Medical University of South Carolina

aTyr Pharma, Inc. announced that it has entered into a research collaboration with the Medical University of South Carolina.
[aTyr Pharma, Inc.]

Press Release

Boehringer
Ingelheim Begins Phase II Clinical Trial of a Targeted Therapy to Help People with Severe Respiratory Illness from COVID-19

Boehringer Ingelheim announced the initiation of a Phase II clinical trial of BI 764198, an inhibitor of TRPC6, a receptor-operated cation channel. This potent and selective inhibitor of TRPC6 may alleviate the damage to the lung and decrease the risk or severity of acute respiratory complications in patients hospitalized for COVID-19.
[Boehringer Ingelheim International GmbH]

Press Release

FEATURED EVENT

Identification of SARS-CoV-2 Inhibitors using Lung and Colonic Organoids

Exuberant Fibroblast Activity Compromises Lung Function via ADAMTS4

Mutant CFTR Drives TWIST1 Mediated Epithelial–Mesenchymal Transition

The
SARS-CoV-2 Targets by the PscRNA Profiling of ACE2, TMPRSS2 and Furin Proteases

A
High Content Screen for Mucin-1-Reducing Compounds Identifies Fostamatinib as a Candidate for Rapid Repurposing for Acute Lung Injury

Upregulation
of KCNQ1OT1 Promotes Resistance to Stereotactic Body Radiotherapy in Lung Adenocarcinoma by Inducing ATG5/ATG12-Mediated Autophagy via miR-372-3p

SASH1
Is a Prognostic Indicator and Potential Therapeutic Target in Non-Small Cell Lung Cancer

Plasma-Activated
Medium as Adjuvant Therapy for Lung Cancer with Malignant Pleural Effusion

ERK3/MAPK6 Is Required for KRAS-Mediated NSCLC Tumorigenesis

Lung
Gene Expression Signatures Suggest Pathogenic Links and Molecular Markers for Pulmonary Tuberculosis, Adenocarcinoma and Sarcoidosis

Less
Is More: Rare Pulmonary Neuroendocrine Cells Function as Critical Sensors in Lung

Arcus to Collaborate with AstraZeneca on Registrational Trial for Domvanalimab, Arcus’s Novel Anti-TIGIT Antibody, Plus Imfinzi^® in Stage III NSCLC

aTyr
Pharma Announces Research Collaboration with Medical University of South Carolina

Boehringer
Ingelheim Begins Phase II Clinical Trial of a Targeted Therapy to Help People with Severe Respiratory Illness from COVID-19

Keystone
Symposia: Single Cell Biology

> See All Events

Faculty
Position – Oncology & Lung Cancer

Postdoctoral
Fellow – Parenchymal/Vascular Lung Disease

Assistant
Professor – Respirologist

Postdoctoral Fellow – Pharmacogenomics and Integrative Genomics

Postdoctoral
Research Associate – Acute Lung Injury

> See All Jobs